Sagimet Biosciences
NASDAQ: SGMTMenlo Park, US · 5 known investors
Find your way into Sagimet Biosciences
566 people in our graph share verified history with the Sagimet Biosciences team — schools, employers, funds. One of them is your warm intro.
John Torreyunlockedknows Rekha Hemrajani · together at Credit Suisse (overlapped)
×4knows the team · via Credit Suisse
knows the team · via University of Michigan
×2knows the team · via Amgen
×2knows the team · via Heidelberg University
×2knows the team · via P&G Pharmaceuticals
Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology. The company advances drug candidates through clinical trials in areas such as metabolic disease.
Founders & leadership
RH
Rekha HemrajaniinChief Financial Officer, SVP of Business and Financial Operations2015–2016Rekha Hemrajani is an executive leader with background in life sciences strategy, corporate development, finance, and operations, including prior experience in mergers and acquisitions and investment banking.
MP
DH
David HappelChief Executive Officer & Director
AG
Andreas GrauerinChief Medical OfficerHe is a physician-scientist with over 20 years of pharmaceutical industry experience spanning clinical development, medical affairs, and regulatory strategy across therapeutic areas including endocrinology, oncology, and nephrology, and holds an appointment as Associate Professor of Medicine at the University of Heidelberg Medical School.
TC
Thierry ChaucheinChief Financial OfficerThierry Chauche is Chief Financial Officer of Sagimet Biosciences, a clinical-stage biopharmaceutical company developing therapies for metabolic diseases and oncology. He brings experience in biopharma corporate finance, M&A transactions, and investor relations.
MO
Marie O'FarrellinChief Scientific Officer
ER
Elizabeth RozekChief Legal & Administrative Officer
Board
DM
BS
JY
James YoungBoard director
RG
Robert GarlandBoard director
RR
Richard RodgersBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$123.9M disclosed across 4 rounds · 2014–2020
▶$69MraisedJan 2021 · 13 investors · BiotechnologyRule 506(b)
▶$69MraisedJan 2021 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- George KembleExecutive Officer, Director
- Dennis HomExecutive Officer
- Merdad ParseyDirector
- Beth SeidenbergDirector
- Gordon RingoldDirector
- Jason FullerDirector
- James YoungDirector
- Richard RodgersDirector
- Jinzi Jason WuDirector
- Offering amount
- $80M
- Amount sold
- $69M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35.2MraisedFeb 2019 · 19 investors · BiotechnologyRule 506(b)
▶$35.2MraisedFeb 2019 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- George KembleExecutive Officer, Director
- Xufang DuanDirector
- Jason FullerDirector
- Merdad ParseyDirector
- David MottDirector
- Beth SeidenbergDirector
- Richard RodgersDirector
- Gordon RingoldDirector
- Dennis HomExecutive Officer
- Jinzi Jason WuDirector
- James YoungDirector
- Offering amount
- $42.2M
- Amount sold
- $35.2M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.4MraisedJul 2016 · 7 investors · BiotechnologyRule 506(b)
▶$5.4MraisedJul 2016 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James YoungDirector
- David MottDirector
- Beth SeidenbergDirector
- Gordon RingoldDirector
- Jason FullerDirector
- Merdad ParseyDirector
- Richard RodgersDirector
- George KembleExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $5.4M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.3MraisedMar 2015 · 12 investors · BiotechnologyRule 506(b)
▶$14.3MraisedMar 2015 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David MottDirector
- Rekha HemrajaniExecutive Officer
- Beth SeidenbergDirector
- Richard RodgersDirector
- Gordon RingoldDirector
- Merdad ParseyExecutive Officer, Director
- James YoungDirector
- Robert GarlandDirector
- Offering amount
- $35M
- Amount sold
- $14.3M
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$379.7Mvaluation at IPOJan 2024 · $12.50/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Frequently asked questions
- What does Sagimet Biosciences do?
- Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology. The company advances drug candidates through clinical trials in areas such as metabolic disease.
- Who are Sagimet Biosciences's investors?
- Sagimet Biosciences's investors include Altium Capital, HM Venture Partners, Kleiner Perkins, New Enterprise Associates (NEA), Westlake Village BioPartners.
- How much funding has Sagimet Biosciences raised?
- Sagimet Biosciences has disclosed $123.9M raised across 4 rounds.
- Where is Sagimet Biosciences headquartered?
- Sagimet Biosciences is headquartered in Menlo Park, US.